A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis

Trial Profile

A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Voriconazole; Voriconazole
  • Indications Aspergillosis; Cryptococcosis; Zygomycosis
  • Focus Adverse reactions; Registrational
  • Sponsors Asahi Kasei Pharma Corp
  • Most Recent Events

    • 18 Apr 2018 According to a Basilea Pharmaceutica media release, first patient has been enrolled in this study.
    • 18 Apr 2018 According to a Basilea Pharmaceutica media release, results from this study are planned to submit to the Japanese marketing authorizations for isavuconazole for the treatment of deep-seated mycosis.
    • 18 Apr 2018 Status changed from not yet recruiting to recruiting, according to a Basilea Pharmaceutica media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top